Tirzepatide Delivers Cost Savings and Health Gains Over Semaglutide

When evaluating tirzepatide vs semaglutide cost, tirzepatide administered at its maximum tolerated dose produces lower aggregate expenditures and greater quality-adjusted life years than semaglutide at its maximum tolerated dose when both are added to lifestyle intervention. The lifetime simulation yields per-patient savings of $41,688 together with an incremental net health benefit of 0.784 at the $150,000 willingness-to-pay threshold, confirming dominance. These results rest exclusively on head-to-head observations from the SURMOUNT-5 trial population without type 2 diabetes. Novo Nordisk spokesperson noted limitations in the SURMOUNT-5 study being an open label study and stated that “the results from SURMOUNT-5 are not consistent with what we have seen in the STEP trials with Wegovy and in real-world evidence studies.”

Tirzepatide vs Semaglutide Cost Evaluation

An individual patient simulation tracks each participant’s cardiometabolic trajectory by updating body weight, systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol, and glycated hemoglobin at every modeled interval. After the 72-week trial period, parameter values remain stable until discontinuation, after which they revert linearly to baseline over two years; risk equations then translate these trajectories into incidence of type 2 diabetes, cardiovascular disease, and obstructive sleep apnea. The framework incorporates both payer-borne medical costs and productivity losses valued by the human-capital method, with all outcomes discounted at 3 percent annually.

Projected Clinical and Economic Outcomes

Across 1,000 simulated patients, tirzepatide is projected to avert 70 incident type 2 diabetes cases and 10 cardiovascular events while shortening the cumulative time spent with moderate or severe obstructive sleep apnea by 3.07 years relative to semaglutide. At week 72, 87.50 percent of tirzepatide-treated individuals achieve normoglycemia compared with 76.88 percent of semaglutide-treated individuals, and annual work-productivity losses decline by an average of five days per patient. Novo Nordisk spokesperson observed that “in the SURMOUNT-5 trial, the amount of weight loss for Wegovy® was lower than what we showed in the semaglutide clinical trial STEP-1 with approximately 17% average weight loss, and about a third losing 20% or more,” adding that the company has “clear and consistent evidence of a 17% weight loss and about a third of people losing 20% or more in our STEP clinical trial programme and real-world evidence.” Deterministic and probabilistic sensitivity analyses show that tirzepatide remains less costly and more effective under nearly all parameter variations, with discontinuation rates and weight-change magnitude exerting the largest influence on incremental net health benefit. Eli Lilly did not respond to the interview request.

Ad

Broader Implications for Payers and Formularies

The direct use of SURMOUNT-5 comparative efficacy data removes reliance on network meta-analysis and supplies a transparent basis for value dossiers submitted to US payers. Inclusion of productivity effects alongside clinical-event offsets illustrates how societal-perspective evaluations can strengthen arguments for preferred formulary placement. Scenario results that retain dominance even when net drug prices are substituted indicate that the economic advantage may be robust to confidential discounting arrangements commonly encountered in reimbursement negotiations. Further modeling is needed to confirm that tirzepatide vs semaglutide cost advantages persist across varied adherence patterns, price sensitivities and data sources, offering decision-makers reliable data for long-term budget planning.